Tiziana Life Sciences Ltd Ordinary Shares TLSA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Tiziana Doses Last Patient in Phase 2 Trial of Intranasal Foralumab for Mild Alzheimer’s Disease
-
Tiziana Life Sciences Files for Orphan Drug Designation with the FDA for Intranasal Foralumab for the Treatment of Multiple System Atrophy (MSA)
-
Tiziana Announces Last Patient Completes Last Visit in Phase 2a INFORM-MS Trial of Intranasal Foralumab
-
Tiziana Life Sciences Announces Signing of MOU with King Abdullah International Medical Research Center
-
Tiziana Life Sciences Announces Poster Presentation on Phase 2a BANYAN Clinical Trial of Intranasal Foralumab at ALS Nexus 2026
-
Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer
-
Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer
-
Tiziana Reports Reduction in Brain Inflammation in Third Multiple System Atrophy Patient Treated with Intranasal Foralumab
Trading Information
- Previous Close Price
- $1.05
- Day Range
- $1.03–1.10
- 52-Week Range
- $0.76–2.10
- Bid/Ask
- $1.03 / $1.14
- Shares Outstanding
- 127.26M
- Market Cap
- $133.62M
- Volume/Avg
- 563,221 / 748,071
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic Lateral Sclerosis. The company's mission is to design and deliver next-generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's main immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, and other CNS indications.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 10
Valuation
|
Metric
|
TLSA
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
TLSA
|
|---|---|
Quick Ratio | 0.69 |
Current Ratio | 0.69 |
Interest Coverage | −6,295.50 |
Quick Ratio
TLSA
Profitability
|
Metric
|
TLSA
|
|---|---|
Return on Assets (Normalized) | −170.30% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −846.08% |
Return on Assets
TLSA
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|&fx@^<J | LOCK|d&^$d | $127B | |||
| Moderna Inc
MRNA
| LOCK|s#!vG! | LOCK|X!$ | $87B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|YMv<K$ | LOCK|t%pg | $81B | |||
| argenx SE ADR
ARGX
| LOCK|?KH??VK | LOCK|Yz< | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|^^RFMv% | LOCK|dRs | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|&DmZ?V | LOCK|N<s& | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|>x&?fgZ% | LOCK|N@&! | $27B | |||
| Incyte Corp
INCY
| LOCK|Q@Vm!$^ | LOCK|MzN | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|^^NxW@ | LOCK|G> | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|>bmhq? | LOCK|F< | $14B |
United States